COVID-19 Report #4: AHS COVID-19 Scientific Advisory Group
The "experts" who made sure Albertans didn't get Ivermectin, because of conspiracy theories.
Welcome to the fourth instalment of COVID-19 Reports. Today, I’ll be zeroing in on the Alberta Health Services COVID-19 Scientific Advisory Group.
I want to use this opportunity to covertly signal to you, reader, and our allies that this particular report has been provided to a group of officials who I will not name, but are in a position to take action based on the conflicts of interest outlined in this report.
I’ve already said too much. But just know that there is movement. The courts are slow and law enforcement is confused, politicians are blind and the general public is mesmerized. But hold strong. To quote the statement Major Joseph Murphy offered to Project Veritas in their latest exposé:
“To those seeking answers, I offer encouragement. There are good people striving for the truth, working together in and out of government, and they succeed.”
An important note: everything I write about is fully sourced, referenced and cited. I’m not making anything up. I am not unbiased, but I am deeply committed to evidence-based science and reporting, and will do nothing less than that here. Most importantly, all my resources are included for you to “fact-check” for yourself and evaluate their reliability and verifiability.
COVID-19 Report #4: AHS COVID-19 Scientific Advisory Group
Executive Summary
The COVID-19 Scientific Advisory Group that advises Alberta Health Services on its COVID-19 response is primarily made up of members with strong historical and current relationships to pharmaceutical companies and supra-national organizations. This has resulted in what is likely a fundamentally biased process of evaluating data and evidence in order to implement policies that are of personal or professional gain, whether or not this was the intention of the members of the group.
The blocking of the use of Ivermectin as an early treatment option for COVID-19 and the universal application of vaccine products as the solution to the pandemic is a clear result of policies that favour the pharmaceutical companies these individuals receive money from and otherwise work with, and the public statements arguing against early treatment and on behalf of vaccine mandates are based on false premises and very flimsy arguments.
The Chairs of the group are the most conflicted, with one specializing in reducing costs for healthcare providers/selecting which drugs should be funded publicly, and the other making overtly political statements including while dismissing contrary medical perspectives;
Members of the group have received direct payments from the following pharmaceutical companies: AllerGen, Astellas, Baxter, Bristol-Myers Squibb, Janssen, Pfizer, Roche, and Sanofi;
They have further received funding directly or indirectly through their institutions and associated organizations from the following pharmaceutical and medical equipment/supply/analytics/retail companies: Abbott, Actelion, Alexion, Almirall, Amgen, Aniara Diagnostica, Ansell, Aspen Pharmacare, AstraZeneca, Avir Pharma, Baxter, Bayer, Bellco, Biodextris, Biogen, bioMérieux, Boehringer Ingelheim, Boston Scientific, Cardinal Health, CardioMed Supplies, Charles River, Chief Medical Supplies, Chinook Therapeutics, Daiichi Sankyo, DiaSorin, Eli Lilly, Fresenius, Gambro, GlaxoSmithKline, Gilead Sciences, Grifols, Hologic, IMV, InterMune, Janssen, Johnson & Johnson, LEO Pharma, London Drugs, McArthur Medical Sales, Medexus, Medicago, Medtronic, Merck, Moderna, NeuMeDx, Novartis, Novo Nordisk, NxStage, Nycomed, Otsuka, Pfizer, Pharmaceutical Partners of Canada, ProResp, R-Biopharm AG, Roche, Sanofi, Seqirus, Servier, Takeda, Theratechnologies, Trudell Medical, Valneva, VBI Vaccines, Virica Biotech, and VIDO-Intervac;
The funding organizations and associated companies with which the membership engages include Aecon, Bell Media, the Bill & Melinda Gates Foundation, Campbell Collaboration, CN Railway, Cochrane, Corus Entertainment, CTV News, Deloitte, Edmonton Journal, Fidelity, Global News, KPMG, the United States National Institutes of Health, Postmedia, PricewaterhouseCoopers, RBC (Royal Bank of Canada), the Rockefeller Foundation, Scotiabank, Shell, SickKids, TELUS, UNICEF, the University of Oxford, Volvo, WestJet, Wikipedia, and the World Health Organization.
The AHS COVID-19 Scientific Advisory Group must be immediately disbanded, and an investigation undertaken to determine the extent to which public health recommendations were guided by conflicted interests.
Background
Alberta Health Services is the public health authority for the Province of Alberta. It is headquartered in Edmonton, Alberta and reports to the Alberta Ministry of Health.1
On March 11, 2020, the World Health Organization (WHO) declared a pandemic due to COVID-19, the disease believed to be caused by the SARS-CoV-2 virus.2 Alberta Premier Jason Kenney followed suit by declaring a state of public health emergency on March 17, 2020.3
The COVID-19 Scientific Advisory Group was created to provide recommendations to support policy and operational decision-making to the AHS Emergency Coordination Centre. The group reports to the Operations Section Chief at the Emergency Coordination Centre. It answers questions “related to any aspect of COVID-19 including risk for transmission, personal protective equipment, strategies for isolation, treatment strategies, and management of patients in hospitals.”4
The primary membership is the following:
SAG Co-chairs – Dr. Braden Manns; Dr. Lynora Saxinger
Public Health representative – Dr. Alexander Doroshenko
Infectious Disease / IPC Experts – Dr. John Conly
Critical care representative – Dr. Shelley Duggan
General Internal Medicine – Dr. Elizabeth Mackay
Respiratory representative – Dr. Brandie Walker
Emergency department representative – Dr. Andrew McRae
Pharmacy representative - Jeremy Slobodan
Provincial Laboratory – Dr. Nathan Zelyas
Alberta Health Medical Office of Health representative – Dr. Andre Corriveau
Additional contributors are frequently included in the reports generated by the SAG - this report will focus on the core membership.
Braden Manns
Dr. Braden Manns, MD, MSc, FRCPC, is Associate Chief Medical Officer for the Strategic Clinical Networks (SCNs) within Alberta Health Services.5 He is also Co-Chair of the AHS Scientific Advisory Group alongside Lynora Saxinger.
Education
Manns began his post-secondary education with his Bachelor of Science degree with Honours in Biochemistry from the University of Saskatchewan, graduating in 1990.
He received his Doctor of Medicine from the University of Toronto in May 1994, graduating with Honours Standing. He completed a General Internal Medicine Residency at the University of Calgary in 1997, where he was named a Fellow of the Royal College of Physicians and Surgeons of Canada, Internal Medicine the following year. He repeated the process with a Nephrology fellowship in 1999. Manns got his Masters in Health Economics at University of York, England, in October 2000.
He returned to complete a post-doctoral fellowship in Health Economics at the University of Calgary in June 2001.6
Suppression of Ivermectin
In his role as Co-Chair of the SAG, Manns co-authored an article insisting that Ivermectin not be used to treat COVID-19. He and his colleagues falsely claimed that “there is no evidence that ivermectin benefits COVID-19 patients, but there are known harms. Ivermectin use has been associated with rash, nausea, vomiting, low blood pressure, abdominal pain, tremors, seizures and severe hepatitis (liver disease) requiring hospitalization.” The conclusion they reach is “Vaccination remains our best means of preventing COVID-19. Our vaccines are safe, fully approved and have been studied in high quality trials of tens of thousands of people.”7
The comments left by readers overwhelmingly objected to the authors' statements and accused them of negligence, supporting their criticism with references to the British Ivermectin Recommendation Development (BIRD) Group, Pierre Kory, and Sanjay Gupta's heated exchange with Joe Rogan after CNN levelled the same propagandistic claims at him.8 9
Members of the public have described Manns as “corrupt”. Dr. William Makis called for his resignation from the Advisory Group and an investigation into why he and his colleagues blocked Ivermectin.10
Affiliations
Alberta Kidney Disease Network
Manns was a member of the Alberta Kidney Disease Network (AKDN), funded by an unrestricted grant from Amgen.11
Amgen is a pharmaceutical company associated with the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership, funded by the United States National Institutes of Health (NIH), the Bill & Melinda Gates Foundation, the Biomedical Advanced Research and Development Authority (BARDA), the U.S. Centres for Disease Control and Prevention (CDC), the US Food and Drug Administration (FDA), the U.S. Department of Defense (DOD), the European Medicines Agency (EMA) and a plethora of major pharmaceutical companies, among others.12 13
The AKDN website appears to have been discontinued and is available in archived form on the Wayback Machine.
Alberta SPOR Unit
Manns serves on the Steering Committee for the Alberta Strategy for Patient-Oriented Research (SPOR) Unit (AbSPORU).14 AbSPORU is co-funded by Alberta Innovates, which is partnered with Pfizer.15
BC Renal Agency
Manns was a speaker at BC Kidney Days on October 24, 2013. The event was hosted by the BC Renal Agency and BC Transplant, and accredited by the Canadian Society of Nephrology. It was sponsored by Amgen, Baxter, Janssen, Alexion, Bellco, Fresenius, Takeda, Gambro, Roche, Abbott Nutrition, Ansell, CardioMed Supplies, Charles River, Chief Medical Supplies, NxStage, Otsuka, Pfizer, Pharmaceutical Partners of Canada (PPC), and Sanofi.16
Can-SOLVE CKD Network
Manns served as a co-lead for the Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can-SOLVE CKD Network). The initiative is funded by Amgen, Bayer, Chinook Therapeutics, Janssen, Otsuka, and others.17
Canadian Expert Drug Advisory Committee
Manns served a term as Chair of the Canadian Expert Drug Advisory Committee, a committee that recommends which new drugs should be paid for within publicly funded drug formularies.18
Canadian Society of Nephrology
Manns served as President of the Canadian Society of Nephrology, funded by Alexion, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Fresenius, Horizon Therapeutics, Janssen, and Otsuka.19 20
Kidney Foundation of Canada
Manns received the 2017 Medal for Research Excellence from the Kidney Foundation of Canada, stating “his expertise in applied health economics, health outcomes, pharmaceutical review and priority setting has directly informed health policy and decision-making.”21 The Foundation receives significant funding from Otsuka.22
Network of Alberta Health Economists
Manns is a member of the Network of Alberta Health Economists.23
Reformulary
Mann serves as a Special Consultant to Reformulary, a privately-held company that provides drug recommendations.24
University of Calgary
Manns is a Professor in Health Economics and a Kidney Specialist at the University of Calgary. In this role, Manns has advocated for increased Federal spending to pay for high cost pharmaceutical drugs in Canada.25
He also served as co-lead for the University's Interdisciplinary Chronic Disease Collaboration, which was funded by the Pfizer-funded Alberta Innovates.
Funding
Government
Manns has received funding from the Canadian Institutes of Health Research Foundation.26
Manns has also had publications funded by Alberta Innovates, which (once again) is partnered with Pfizer.27
One such study is “COVID-19 Vaccine-Related Attitudes and Beliefs in Canada: National Cross-sectional Survey and Cluster Analysis”, which concluded “Messaging related to preventing COVID among friends and family, highlighting the benefits, emphasizing safety and efficacy of COVID-19 vaccination, and ensuring that health care workers are knowledgeable and supported in their vaccination counselling may be effective for vaccine-hesitant populations.”28
Another is “Characterization of non-adopters of COVID-19 non-pharmaceutical interventions through a national cross-sectional survey to assess attitudes and behaviours”.29
Yet another is “Attitudes, behaviours and barriers to public health measures for COVID-19: a survey to inform public health messaging”.30
Pharmaceutical Companies
Manns has received funding via an unrestricted grant from Baxter.31
Lynora Saxinger
Dr. Lynora Saxinger, CTropMed, MD, FRCPC, is an academic infectious diseases specialist, whose professional career outside patient care is focused on antimicrobial stewardship and antimicrobial resistance, with involvement in hospital, health system and national collaborations to improve antibiotic stewardship practice, and resistance and utilization surveillance.32
Education
Saxinger completed her Bachelor of Science at the University of Saskatchewan in 1992, then her MD in 1996. She became a Fellow of the Royal College of Physicians and Surgeons of Canada in 2000.
Suppression of Ivermectin
Saxinger was an additional author alongside Braden Manns and Mark Joffe insisting Ivermectin not be used to prevent or treat COVID-19.
In an email thread published by Rebel News it was revealed Saxinger was particularly agitated at the notion of recommending the use of Ivermectin, dismissing the suggestion as being based on “misinformation” pushed by Danielle Smith and Fox News.33
Censorship of Opposing Voices
In disturbing irony, Saxinger opined that “more academics and people in medicine should consider what they can contribute to public discussions. If you can step in, it really is an asset to be able to do it. And it might take a bit of practice before you're comfortable, but it really demonstrates and applies our skills in a public way.”34
This is perhaps an example of gaslighting, or an indication that she was ignorant to the widespread censorship of opposing medical voices taking place across Canada and the world during the COVID-19 pandemic.
Affiliations
Alberta Health Services
Saxinger is Co-Chair of COVID-19 Scientific Advisory Group under Alberta Health Services alongside Braden Manns.35 She is also tasked with “engagement in social media and media based scientific communication and knowledge translation for public education around COVID-19.”36 She is Medical Lead of Antimicrobial Stewardship for Northern Alberta for AHS.37
Association of Medical Microbiology and Infectious Diseases Canada
Saxinger is a founding member and past chair of the Antimicrobial Resistance and Stewardship Committee of the Association of Medical Microbiology and Infectious Diseases Canada. She was a speaker at AMMI's 2021 Annual Conference, for a presentation titled “Strategic Deployment of COVID-19 Treatment Options: Who, What, Where and How?”
AMMIDC is partnered with the Canadian College of Microbiologists (CCM), the Canadian Foundation for Infectious Diseases (CFID), the Canadian Medical Association, Choosing Wisely Canada, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), the International Society of Antimicrobial Chemotherapy, and the Pan American Society for Clinical Virology (PASCV).38
The organization receives sponsorship funds from Merck, Gilead Sciences, Seqirus, DiaSorin, Hologic, Roche, Pfizer, Avir Pharma, Moderna, and R-Biopharm AG.39 40
National Collaborating Centre for Infectious Diseases
Saxinger is a partner at the National Collaborating Centre for Infectious Diseases (NCCID) where she was a Principal Investigator of a commissioned 2012 report titled “Antimicrobial Resistance and Utilization Surveillance in Canada”.41
Public Health Agency of Canada
Saxinger has worked as an advisor with the Canadian Hospital Epidemiology Committee/Canadian Nosocomial Infection Surveillance Program (CNISP) collaboration with the Public Health Agency of Canada, as well as with the Canadian Integrated Program for Antimicrobial Resistance in utilization reporting of human antimicrobial use data.42
University of Alberta
Saxinger is an Associate Professor in the Department of Medicine, Division of Infectious Diseases at the University of Alberta.
Funding
Saxinger received a grant under the COVID-19 Evidence Network to support Decision-making (COVID-END) program from the Canadian Institutes of Health Research (CIHR) in 2020. COVID-END is partnered with the Campbell Collaboration, Cochrane, UNICEF, and others, with funds sourced from the Rockefeller Foundation, the World Health Organization, Wikipedia, and others.43 44 45
Alexander Doroshenko
Dr. Alexander Doroshenko is an infectious disease epidemiologist and public health specialist in Alberta, Canada. His interests include evaluation of public health interventions and evidence-based public health policies.
Affiliations
Alberta Health Services
Doroshenko is the Public Health representative for the COVID-19 Scientific Advisory Group under Alberta Health Services.46
University of Alberta
Doroshenko is an Assistant Professor in the Department of Medicine, Faculty of Medicine and Dentistry at the University of Alberta.47
He has received funding for research through the University of Alberta from the University Hospital Foundation, which is funded by Takeda, Biogen, Boehringer Ingelheim, Novartis, Merck, Volvo, Edmonton Journal, Canadian National Railway (part owned by Bill Gates), RBC (Royal Bank of Canada), TELUS, KPMG, Medtronic, Scotia Capital (Scotiabank), Postmedia, Deloitte, Fidelity, London Drugs, WestJet, Aecon, PricewaterhouseCoopers, Janssen, CTV News, Bell Media, Global News, Corus Entertainment, Astellas, Novo Nordisk, Servier, and Roche.48 49 50
Publications
Public health implications of SARS-CoV-2 variants of concern: a rapid scoping review51
Funded by the SPOR Evidence Alliance, Canadian Institutes of Health Research (CIHR), and COVID-END.
Trivalent MDCK cell culture-derived influenza vaccine Optaflu® (Novartis Vaccines)52
Co-authored with Scott Halperin, who has an extensive catalogue of
vaccine-related publications and was funded by Novartis for this study
In collaboration with the Canadian Center for Vaccinology
What We Know Now: An Economic Evaluation of Chickenpox Vaccination and Dose Timing Using an Agent-Based Model53
Funded by Alberta Health Services and the University of Alberta
Decline of Influenza and Respiratory Viruses With COVID-19 Public Health Measures:
Alberta, Canada54
Doroshenko reported receiving personal fees from Sanofi for an advisory role
He also reported that his employer, the University of Alberta, was paid additional funds in research grants from the Canadian Institutes of Health Research (CIHR), Public Health Agency of Canada, Alberta Health Services, and the University Hospital Foundation (also listed as “University of Alberta Hospital Foundation”).
The study found that the public health measures Doroshenko helped put in place were “associated with a substantial reduction in influenza and NIRV infections in Alberta.”
The Combined Effect of Vaccination and Nonpharmaceutical Public Health Interventions-Ending the COVID-19 Pandemic55
Same funding details as previous study
John Conly
Dr. John Conly, MD, CM, CCFP, FRCPC, FCAHS, FAMMI, FACP, FSHEA, FIDSA, is a specialist in infectious diseases in Alberta, Canada.
Affiliations
Alberta Health Services
Conly is an Infectious Disease / IPC Expert for the COVID-19 Scientific Advisory Group under Alberta Health Services.56
Alberta Medical Association
Conly received the Medal for Distinguished Service from the Alberta Medical Association for “outstanding personal contributions to the medical profession”.
AMR One Health Consortium
Conly is a Work Package Lead, Principal Investigator, and Executive Committee member of the Antimicrobial Resistance (AMR) One Health Consortium.
Canadian Committee on Antibiotic Resistance
Conly served as Chairman of the Board for the Canadian Committee on Antibiotic Resistance (CCAR).
Canadian Expert Advisory Group on Antimicrobial Resistance
Conly is a member of the Canadian Expert Advisory Group on Antimicrobial Resistance (CEAGAR).
Canadian Expert Drug Advisory Committee
Conly served as Vice Chair of the Canadian Expert Drug Advisory Committee (CEDAC).
Canadian Infectious Disease Society
Conly formerly served as President of the Canadian Infectious Disease Society (CIDS).
University of Calgary
Conly is a Professor of Medicine, Microbiology, Immunology & Infectious Diseases, Pathology & Laboratory Medicine in the Department of Medicine (Infectious Diseases), Cumming School of Medicine, University of Calgary, where he is also the former Head of the Department of Medicine, and the Co-Director for the Snyder Institute for Chronic Diseases.57
W21C
Conly is the Medical Director of W21C, a research and innovation initiative based in the University of Calgary and the Calgary Zone of Alberta Health Services (AHS).58 59
It is funded by the Government of Canada through a Western Economic Partnership Agreement (WEPA), and later received funding from Alberta Health and Wellness (AH&W), Alberta Innovates, Alberta Ministry of Jobs, Economy, and Innovation, Western Economic Diversification Canada, and Innovate Calgary.
World Health Organization
Conly is a member of the World Health Organization Advisory Group on Integrated Surveillance of Antimicrobial Resistance. He is overseeing the Calgary study site of the WHO's “Case-control study to assess risk factors for SARS-CoV-2 infection among healthcare workers” under the UNITY Studies project.60
Relationships with Pharmaceutical Companies
Conly has received funding from Pfizer via the University of Calgary to conduct its STRIVE S. aureus vaccine randomized clinical trial.61 He previously received speaker's fees from Janssen, Pfizer, and Astellas.62
Shelley Duggan
Affiliations
Alberta Health Services
Duggan is a critical care representative in the COVID-19 Scientific Advisory Group under Alberta Health Services.63
Alberta Medical Association
Duggan sits on the Board of Directors at the Alberta Medical Association.64 She has been an AMA member since 2002. She is an AMA Representative Forum delegate, president of the Edmonton Zone Medical Staff Association and is treasurer for the AMA Section of Nephrology. In the past she was president of the AMA Section of Nephrology.
Covenant Health
Duggan is a staff physician in Critical Care and Nephrology at the Grey Nuns Community Hospital under Covenant Health.
University of Alberta
Duggan is a clinical professor in the Department of Medicine at the University of Alberta.65
Media Appearances
Dr. Duggan “enjoys educating the public in her role as Ask the Doctor” on Global News.
Elizabeth MacKay
Affiliations
Alberta Health Services
MacKay is a General Internal Medicine representative on the COVID-19 Scientific Advisory Group under Alberta Health Services.66
Relationships with Pharmaceutical Companies
MacKay has received personal fees from Pfizer and Bristol-Myers Squibb.67
Brandie Walker
Affiliations
Alberta Health Services
Walker is the respiratory representative on the COVID-19 Scientific Advisory Group under Alberta Health Services.
Canadian Lung Association
Walker is a researcher for the Canadian Lung Association. She received the Clinician-Scientist Asthma Award, which provided her with $115,000.00 in funding from AllerGen, the Canadian Lung Association and the Canadian Thoracic Society.68
The CLA is partnered with Actelion (now a Johnson & Johnson company), AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Grifols, InterMune, McArthur Medical Sales, Pediapharm (now called Medexus), Merck, Novartis, Pfizer, ProResp, RBC (Royal Bank of Canada), Roche, Takeda, and Trudell Medical.69 70 71 72 73 74
University of Calgary
Walker is a Clinical Associate Professor of Medicine at the University of Calgary's Snyder Institute for Chronic Diseases (in partnership with Alberta Health Services).75 Her research focus is in the field of airways diseases with a focus on COPD and asthma.
Relationships with Pharmaceutical Companies
Through her participation in the CanCOLD study, Walker has received funding from Almirall, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, NeuMeDx, Novartis, Nycomed, Pfizer, Takeda, and Theratechnologies.76
Andrew McRae
Affiliations
Alberta Health Services
McRae is the emergency department representative for the COVID-19 Scientific Advisory Group under Alberta Health Services.
Canadian Medical Association
McRae is an Editorial Fellow at the Canadian Medical Association Journal.77 78 In this capacity, McRae co-authored an editorial titled “SARS-CoV-2 vaccination should be required to practise medicine in Canada".79
Ottawa Hospital
McRae is a collaborator on a project that addresses ethical and policy challenges posed by cluster randomized trials, in partnership with the Rotman Institute of Philosophy and the Ottawa Hospital Research Institute, funded by the Canadian Institutes of Health Research.80
The OHRI has received funding for research from Pfizer for research on drugs for advanced lung cancer,81 kidney transplant patients,82 83 and blood clots in cancer patients.84 85
Bristol-Myers Squibb also funded the latter study, as did CanVECTOR, which is funded by Alexion, Aniara Diagnostica, Aspen Pharmacare, Bayer, bioMérieux, Boston Scientific, Bristol-Myers Squibb, Cardinal Health, Daiichi Sankyo, LEO Pharma, Pfizer, and Sanofi.86
Another study looking at blood thinners in pregnancy was also funded by Pfizer, as well as Eli Lilly.87 88
Other pharmaceutical research funders are AstraZeneca,89 Janssen,90 and GlaxoSmithKline.91
University of Calgary
McRae is a Researcher and Assistant Professor at the University of Calgary's Department of Emergency Medicine, a partnership between Alberta Health Services and the Cumming School of Medicine.92 He has a cross-appointment to the Department of Community Health Sciences. In addition to active research interests in emergency department crowding and operations, his primary interest is in health services dimensions of the diagnosis and treatment of cardiovascular emergencies (myocardial infarction, arrhythmias, stroke).
Western University
McRae was a Postdoctoral Fellow at the Rotman Institute of Philosophy at Western University from 2009 – 2011.93
Relationships with Pharmaceutical Companies
McRae received an unrestricted research grant from Roche for 2021-2022.94
Jeremy Slobodan
Affiliations
Alberta Health Services
Slobodan is a pharmacy representative in the COVID-19 Scientific Advisory Group under Alberta Health Services. He is also the Director of Drug Utilization, Information & Stewardship.95
Nathan Zelyas
Dr. Nathan Zelyas is a medical microbiologist in Alberta, Canada. He is one of “about 20” such specialists in the province.96 During the COVID-19 pandemic, Dr. Zelyas supported the implementation of molecular diagnostic testing for SARS-CoV-2 infections in Alberta.97
Affiliations
Alberta Health Services
Zelyas is the Provincial Laboratory representative for the COVID-19 Scientific Advisory Group under Alberta Health Services.
Alberta Precision Labs
Zelyas is a Medical Microbiologist at Alberta Precision Laboratories, and is the APL Public Health Program leader for Respiratory Viruses.98
University of Alberta
Zelyas is Program Director for the Medical Microbiology Residency Program at the University of Alberta.99
Publications
August 11, 2021: Precision Response to the Rise of the SARS-CoV-2 B.1.1.7 Variant of Concern by Combining Novel PCR Assays and Genome Sequencing for Rapid Variant Detection and Surveillance100
Funded by the Canadian COVID-19 Genomics Network (CanCOGeN) supported by Genome Alberta and Genome Canada.
The Board of Directors for Genome Canada includes representatives from Bayer, the Bill & Melinda Gates Foundation, the United States National Institutes of Health (NIH), Shell, SickKids, and the University of Oxford. They also received funding from BIOTECanada (AstraZeneca, Biodextris, GlaxoSmithKline, IMV, Janssen, Medicago, Merck, Pfizer, Sanofi, Valneva, VBI Vaccines, Virica Biotech, and VIDO-Intervac, which is conducting COVID-19 vaccine research with the People’s Republic of China)101 102 103
André Corriveau
Dr. André Corriveau was the Chief Medical Officer of Health (CMOH) for the Province of Alberta from 2009 until 2012.104
Affiliations
Alberta Health Services
Corriveau is the Alberta Health Medical Office of Health representative in the COVID-19 Scientific Advisory Group under Alberta Health Services.66 He was formerly the Chief Medical Officer of Health for the Province of Alberta, and was in this position during the 2009 H1N1 Swine Flu outbreak. He resigned in March 2012.105
Canadian Partnership Against Cancer
Corriveau is a member of the Board of Directors for the Canadian Partnership Against Cancer as a health system expert.106
The Board of Directors for the CPAC include representation from PricewaterhouseCoopers, the Ontario Ministry of Health, Fraser Health Authority, Dalhousie University, University of Calgary, Health Canada, OntarioMD, Quebec Ministry of Health and Social Services, British Columbia Ministry of Health, PEI Department of Health and Wellness, and the Canadian Cancer Society.107
The CPAC provided funding to Alberta Health Services, with whom Corriveau is also associated, in 2020 and 2021.
Canadian Water Network
Corriveau is a Health Services Delivery and Public Health consultant on the Public Health Advisory Group for the Canadian Water Network.108
Government of Northwest Territories
Corriveau served as Chief Public Health Officer (CPHO) for the Department of Health and Social Services in the Northwest Territories from 1998 to 2009. He was re-appointed to the position in June 2012 following his time as the CMOH of Alberta.109
University of Calgary
Corriveau is an Adjunct Professor in the Faculty of Medicine at the University of Calgary.
Wikipedia Contributors. (2019, November 2). Alberta Health Services. Wikipedia; Wikimedia Foundation. https://archive.ph/SJG40
Cucinotta, D., & Vanelli, M. (2020). WHO Declares COVID-19 a Pandemic. Acta bio-medica : Atenei Parmensis, 91(1), 157–160. https://doi.org/10.23750/abm.v91i1.9397
“This is a serious moment in our history”: Alberta Premier Jason Kenney declares public health emergency. (2020, March 17). CBC News; CBC/Radio-Canada. https://archive.ph/I1frj
2019-nCoV Scientific Advisory Group. (2021, May 27). Alberta Health Services. https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-sag-terms-of-reference.pdf
Manns, B. (2018). Introducing Braden Manns. Alberta Health Services. https://www.albertahealthservices.ca/assets/about/scn/ahs-scn-pfe-newsletter-braden-manns.pdf
Manns, B. (2015, July). BRADEN MANNS, MD, MSc, FRCPC - CV. https://contacts.ucalgary.ca/info/chs/profiles/1-4840509/braden-j-manns-cv.pdf
Manns, B., Saxinger, L., & Joffe, M. (2021, October 12). Alberta Health Services: Ivermectin is a useful drug, but not a treatment for COVID-19. MSN News; Calgary Herald. https://archive.ph/11Xqr
Heine, D. (2021, October 14). Joe Rogan Confronts CNN’s Dr. Sanjay Gupta on Network’s COVID Lies. American Greatness. https://archive.ph/mKmiP
Manns, B., Saxinger, L., & Joffe, M. (2021, October 12). Alberta Health Services: Ivermectin is a useful drug, but not a treatment for COVID-19. Calgary Herald; Postmedia Network Inc. https://calgaryherald.com/opinion/columnists/alberta-health-services-ivermectin-is-a-useful-drug-but-not-a-treatment-for-covid-19
@MakisMD. (2021, June 15). We first need a full Investigation of the AHS COVID-19 Scientific Advisory Group lead by NDP/AHS Executive Braden Manns and his associates like @AntibioticDoc and @drslmd. Twitter. https://archive.ph/lFAhb
Our Team. (2017, October 23). Alberta Kidney Disease Network. https://web.archive.org/web/20171023095419/https://www.akdn.info/our-team
ACTIV. National Institutes of Health (NIH). Retrieved January 10, 2022, from https://archive.ph/8eMTV
Our Response to Covid-19. Amgen. Retrieved January 10, 2022, from https://archive.ph/NHHFE
About Us. Alberta Strategy for Patient Oriented Research SUPPORT Unit (AbSPORU). Retrieved January 8, 2022, from https://archive.ph/3eRHR
Brunner, D. (2018, November 26). Alberta Government and Pfizer Canada boosts provincial collaborative health innovation partnership with Alberta Innovates. Alberta Innovates. https://archive.ph/1ppaw
Compassion in Kidney Care: From Patients to Providers. BC Renal Agency. Retrieved January 8, 2022, from http://www.bcrenal.ca/resource-gallery/Documents/Final_program_design_web.pdf
Funding Partners. Can-SOLVE CKD Network. Retrieved January 8, 2022, from https://cansolveckd.ca/about/funding-partners/
Manns, B. (2007, April 25). Dr. Braden Manns (Chair, Canadian Expert Drug Advisory Committee, Canadian Agency for Drugs and Technologies in Health) at the Health Committee. Open Parliament. https://openparliament.ca/committees/health/39-1/50/dr-braden-manns-1/only/
Our Partners. CSN/SCN. Retrieved January 8, 2022, from https://archive.ph/Omio2
HE Braden Manns. O’Brien Institute for Public Health. Retrieved January 8, 2022, from https://obrieniph.ucalgary.ca/research/centres-programs-research-groups-and-units/health-economics/meet-our-team/dr-braden-mann s-0
Dr. Braden Manns. Kidney Foundation of Canada. Retrieved January 8, 2022, from https://archive.ph/yLyCY
Virtual Forum 2022. Kidney Foundation of Canada. Retrieved January 8, 2022, from https://archive.ph/lbb0R
Our Members. Network of Alberta Health Economists. Retrieved January 8, 2022, from https://noahe.ca/members#
About Us. Reformulary. Retrieved January 8, 2022, from https://archive.ph/KktHK
Manns, B., & Clement, F. (2017, November 1). A Different Prescription-Pharmacare isn’t the only solution to high drug costs. Alberta Views - the Magazine for Engaged Citizens. https://archive.ph/znmjx
Trachtenberg, A. J., Quinn, A. E., Ma, Z., Klarenbach, S., Hemmelgarn, B., Tonelli, M., Faris, P., Weaver, R., Au, F., Zhang, J., & Manns, B. (2020). Association between change in physician remuneration and use of peritoneal dialysis: a population-based cohort analysis. CMAJ Open, 8(1), E96–E104. https://doi.org/10.9778/cmajo.20190132
Partnerships and Alliances. (2019, December 3). Pfizer Canada. https://archive.ph/W6hj7
Benham, J. L., Atabati, O., Oxoby, R. J., Mourali, M., Shaffer, B., Sheikh, H., Boucher, J.-C., Constantinescu, C., Parsons Leigh, J., Ivers, N. M., Ratzan, S. C., Fullerton, M. M., Tang, T., Manns, B. J., Marshall, D. A., Hu, J., & Lang, R. (2021). COVID-19 Vaccine–Related Attitudes and Beliefs in Canada: National Cross-sectional Survey and Cluster Analysis. JMIR Public Health and Surveillance, 7(12), e30424. https://doi.org/10.2196/30424
Lang, R., Atabati, O., Oxoby, R. J., Mourali, M., Shaffer, B., Sheikh, H., Fullerton, M. M., Tang, T., Leigh, J. P., Manns, B. J., Marshall, D. A., Ivers, N. M., Ratzan, S. C., Hu, J., & Benham, J. L. (2021). Characterization of non-adopters of COVID-19 non-pharmaceutical interventions through a national cross-sectional survey to assess attitudes and behaviours. Scientific Reports, 11(1). https://doi.org/10.1038/s41598-021-01279-2
Lang, R., Benham, J. L., Atabati, O., Hollis, A., Tombe, T., Shaffer, B., Burns, K. K., MacKean, G., Léveillé, T., McCormack, B., Sheikh, H., Fullerton, M. M., Tang, T., Boucher, J.-C., Constantinescu, C., Mourali, M., Manns, B. J., Marshall, D. A., Hu, J., & Oxoby, R. J. (2021). Attitudes, behaviours and barriers to public health measures for COVID-19: a survey to inform public health messaging. BMC Public Health, 21(1). https://doi.org/10.1186/s12889-021-10790-0
Trachtenberg, A. J., Quinn, A. E., Ma, Z., Klarenbach, S., Hemmelgarn, B., Tonelli, M., Faris, P., Weaver, R., Au, F., Zhang, J., & Manns, B. (2020). Association between change in physician remuneration and use of peritoneal dialysis: a population-based cohort analysis. CMAJ Open, 8(1), E96–E104. https://doi.org/10.9778/cmajo.20190132
Faculty of Medicine & Dentistry. DR. LYNORA SAXINGER. University of Alberta. Retrieved January 8, 2022, from https://archive.ph/Hm7d4
Gunn Reid, S. (2021, October 28). EXCLUSIVE: Internal emails show Alberta doctor had Ivermectin use request denied by AHS. Rebel News. https://archive.ph/8EgIC
Bauer, K. (2020, September 16). Pandemic Perspectives: Lynora Saxinger. University of Alberta. https://archive.ph/qHWYd
2019-nCoV Scientific Advisory Group. (2021, May 27). Alberta Health Services. https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-sag-terms-of-reference.pdf
Final Program - 2021 Annual Conference. AMMI. Retrieved January 8, 2022, from https://www.ammi.ca/Content/2021%20Final%20Program_FINAL.pdf
ASC Terms of Reference. (2019, February). Alberta Health Services. https://www.albertahealthservices.ca/assets/info/hp/as/if-hp-antimicrobial-stewardship-tor.pdf
Partnerships. Association of Medical Microbiology and Infectious Disease Canada. Retrieved January 8, 2022, from https://archive.ph/Uzsmx
Sponsorship & Exhibitor Prospectus. (2021, December). Association of Medical Microbiology and Infectious Diseases Canada. https://ammi.ca/wp-content/uploads/2021/12/2022-Sponsorship-.Exhibitor-ProspectusFINAL.pdf
2021 Annual Conference. AMMI. Retrieved January 8, 2022, from https://archive.ph/PLAHX
Lynora Saxinger. (2015, March 30). National Collaborating Centre for Infectious Diseases. https://archive.ph/TKd0U
Haworth-Brockman, M., Saxinger, L. M., Miazga-Rodriguez, M., Wierzbowski, A., & Otto, S. J. G. (2021). One Health Evaluation of Antimicrobial Use and Resistance Surveillance: A Novel Tool for Evaluating Integrated, One Health Antimicrobial Resistance and Antimicrobial Use Surveillance Programs. Frontiers in Public Health, 9. https://doi.org/10.3389/fpubh.2021.693703
Our sponsors. Campbell Collaboration. Retrieved January 8, 2022, from https://archive.ph/eY8az
Partners. McMaster Health Forum. Retrieved January 8, 2022, from https://www.mcmasterforum.org/networks/covid-end/about-covid-end/partners
Our funders and partners. Cochrane. Retrieved January 8, 2022, from https://archive.ph/IdMAG
2019-nCoV Scientific Advisory Group. (2021, May 27). Alberta Health Services. https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-sag-terms-of-reference.pdf
Alexander Doroshenko | Public Health. University of Alberta. Retrieved January 8, 2022, from https://www.ualberta.ca/public-health/about/faculty-staff/adjunct-emeritus-faculty/doroshenko.html
Abbott, J. (2021). Thank you to our donors. University Hospital Foundation (pp. 2–23). https://givetouhf.ca/app/uploads/2021/12/UHF-2021-HonouringDonors-WEB-v2.pdf
Annual Report 2019-2020. University Hospital Foundation. Retrieved January 8, 2022, from https://givetouhf.ca/app/uploads/2021/08/UHF_Annual-Report-2019-2020-Revised_19412_F-pages-smaller.pdf
Annual Report 2018-2019. University Hospital Foundation. Retrieved January 8, 2022, from https://givetouhf.ca/app/uploads/2020/10/UHF-Annual-Report-2018-19-lowres.pdf
Somerville, M., Curran, J. A., Dol, J., Boulos, L., Saxinger, L., Doroshenko, A., Hastings, S., Reynolds, B., Gallant, A. J., Shin, H. D., Wong, H., Crowther, D., Macdonald, M., Martin-Misener, R., Comeau, J., McCulloch, H., & Tricco, A. C. (2021). Public health implications of SARS-CoV-2 variants of concern: a rapid scoping review. BMJ Open, 11(12), e055781. https://doi.org/10.1136/bmjopen-2021-055781
Doroshenko, A., & Halperin, S. A. (2009). Trivalent MDCK cell culture-derived influenza vaccine Optaflu® (Novartis Vaccines). Expert Review of Vaccines, 8(6), 679–688. https://doi.org/10.1586/erv.09.31
Rafferty, E. R. S., McDonald, W., Osgood, N. D., Doroshenko, A., & Farag, M. (2021). What We Know Now: An Economic Evaluation of Chickenpox Vaccination and Dose Timing Using an Agent-Based Model. Value in Health, 24(1), 50–60. https://doi.org/10.1016/j.jval.2020.10.004
Doroshenko, A., Lee, N., MacDonald, C., Zelyas, N., Asadi, L., & Kanji, J. N. (2021). Decline of Influenza and Respiratory Viruses With COVID-19 Public Health Measures. Mayo Clinic Proceedings, 96(12), 3042–3052. https://doi.org/10.1016/j.mayocp.2021.09.004
Doroshenko, A. (2021). The Combined Effect of Vaccination and Nonpharmaceutical Public Health Interventions—Ending the COVID-19 Pandemic. JAMA Network Open, 4(6), e2111675. https://doi.org/10.1001/jamanetworkopen.2021.11675
2019-nCoV Scientific Advisory Group. (2021, May 27). Alberta Health Services. https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-sag-terms-of-reference.pdf
John Conly. University of Calgary. Retrieved January 8, 2022, from https://research.ucalgary.ca/amr/people/investigators/john-conly
Dr. John Conly, CM, MD. W21C. Retrieved January 8, 2022, from https://archive.ph/Go60B
About. W21C. Retrieved January 8, 2022, from https://archive.ph/1DFCp
Early investigations protocols. World Health Organization. Retrieved January 9, 2022, from https://archive.ph/5vFGC
McCubbin, K. D., Anholt, R. M., de Jong, E., Ida, J. A., Nóbrega, D. B., Kastelic, J. P., Conly, J. M., Götte, M., McAllister, T. A., Orsel, K., Lewis, I., Jackson, L., Plastow, G., Wieden, H.-J., McCoy, K., Leslie, M., Robinson, J. L., Hardcastle, L., Hollis, A., & Ashbolt, N. J. (2021). Knowledge Gaps in the Understanding of Antimicrobial Resistance in Canada. Frontiers in Public Health, 9. https://doi.org/10.3389/fpubh.2021.726484
Conly, J. M. (2012). Antimicrobial resistance programs in Canada 1995-2010: a critical evaluation. Antimicrobial Resistance and Infection Control, 1(1), 10. https://doi.org/10.1186/2047-2994-1-10
2019-nCoV Scientific Advisory Group. (2021, May 27). Alberta Health Services. https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-sag-terms-of-reference.pdf
Dr. Shelley L. Duggan. (2016, November 17). Alberta Medical Association. https://archive.ph/g0mRa
Shelly Duggan | Department of Critical Care. University of Alberta. Retrieved January 9, 2022, from https://archive.ph/XkhrC
2019-nCoV Scientific Advisory Group. (2021, May 27). Alberta Health Services. https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-sag-terms-of-reference.pdf
Douketis, J. D., Spyropoulos, A. C., Duncan, J., Carrier, M., Le Gal, G., Tafur, A. J., Vanassche, T., Verhamme, P., Shivakumar, S., Gross, P. L., Lee, A. Y. Y., Yeo, E., Solymoss, S., Kassis, J., Le Templier, G., Kowalski, S., Blostein, M., Shah, V., MacKay, E., & Wu, C. (2019). Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2019.2431
Dr. Brandie Walker. (2014, July 25). Canadian Lung Association. https://archive.ph/DDQud
About Us. (2014, August 21). Canadian Lung Association. https://archive.ph/XNGx1
2020/2021 Annual Report. Lung Association of Canada. Retrieved January 10, 2022, from https://www.lung.ca/sites/default/files/LungAssociation_AnnualReport_2020_2021_EN_FIN.pdf
2019/2020 Annual Report. Canadian Lung Association. Retrieved January 10, 2022, from https://www.lung.ca/sites/default/files/LungAssociation_AnnualReport_2019_2020_EN.pdf
2017/2018 Annual Report. Canadian Lung Association. Retrieved January 10, 2022, from https://www.lung.ca/sites/default/files/CLA_AnnualReport2017_2018_EN_FINALSEPT21.pdf
2016/2017 Annual Report. Canadian Lung Association. Retrieved January 10, 2022, from https://www.lung.ca/sites/default/files/LungAssociation_AnnualReport_2016_2017_ENGLISHOCTOBER.pdf
2015/2016 Annual Report. Canadian Lung Association. Retrieved January 10, 2022, from https://www.lung.ca/sites/default/files/LungAssociation_AnnualReport_2015_2016_EN.pdf
Brandie Walker. (2021, February 25). Snyder Institute for Chronic Diseases. https://archive.ph/pOhJW
Home. CanCOLD. Retrieved January 9, 2022, from https://archive.ph/Bp2Fc
McRae, A. @Andrew_McRae_EM. Twitter. Retrieved January 10, 2022, from https://archive.ph/muMc0
Staff | CMAJ. Canadian Medical Association Journal. Retrieved January 10, 2022, from https://archive.ph/Y3t9z
McRae, A. D., & Laupacis, A. (2021). SARS-CoV-2 vaccination should be required to practise medicine in Canada. Canadian Medical Association Journal, cmaj.211839. https://doi.org/10.1503/cmaj.211839
Andrew McRae. The Rotman Institute of Philosophy. Retrieved January 10, 2022, from https://www.rotman.uwo.ca/portfolio-items/mcrae-andrew/#tab-5d6239302fa152c2ec9
Early phase clinical trials shows promising results in advanced lung cancer. (2011, October 12). Ottawa Hospital Research Institute. https://archive.ph/QMO7q
Knoll, G. A., Kokolo, M. B., Mallick, R., Beck, A., Buenaventura, C. D., Ducharme, R., Barsoum, R., Bernasconi, C., Blydt-Hansen, T. D., Ekberg, H., Felipe, C. R., Firth, J., Gallon, L., Gelens, M., Glotz, D., Gossmann, J., Guba, M., Morsy, A. A., Salgo, R., & Scheuermann, E. H. (2014). Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ, 349(nov24 1), g6679–g6679. https://doi.org/10.1136/bmj.g6679
Ganton, J. (2015, October 22). Drugs commonly used in kidney transplant patients not as effective as previously thought. Ottawa Hospital Research Institute. https://archive.ph/SGtWQ
Ganton, J., & Pulkinghorn, I. M. (2018, December 4). Drug dramatically reduces risk of dangerous blood clots in cancer patients. Ottawa Hospital Research Institute. https://archive.ph/n6N5h
Carrier, M., Abou-Nassar, K., Mallick, R., Tagalakis, V., Shivakumar, S., Schattner, A., Kuruvilla, P., Hill, D., Spadafora, S., Marquis, K., Trinkaus, M., Tomiak, A., Lee, A. Y. Y., Gross, P. L., Lazo-Langner, A., El-Maraghi, R., Goss, G., Le Gal, G., Stewart, D., & Ramsay, T. (2019). Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. The New England Journal of Medicine, 380(8), 711–719. https://doi.org/10.1056/NEJMoa1814468
Partners. CanVECTOR. Retrieved January 10, 2022, from https://archive.ph/9TdRm
Ganton, J. (2016, October 18). “Invaluable” study confirms blood thinners don’t prevent recurrent pregnancy complications. Ottawa Hospital Research Institute. https://archive.ph/yTkEU
Rodger, M. A., Gris, J.-C., de Vries, J. I. P., Martinelli, I., Rey, É., Schleussner, E., Middeldorp, S., Kaaja, R., Langlois, N. J., Ramsay, T., Mallick, R., Bates, S. M., Abheiden, C. N. H., Perna, A., Petroff, D., de Jong, P., van Hoorn, M. E., Bezemer, P. D., & Mayhew, A. D. (2016). Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. The Lancet, 388(10060), 2629–2641. https://archive.ph/oithf
Ganton, J. (2016, November 2). Lung cancer breakthrough: 70% of patients with specific mutation respond to new therapy. Ottawa Hospital Research Institute. https://archive.ph/Hm6x5
Buchanan, A. (2016, March 30). When cancer comes back: Drug for mantle-cell lymphoma gives patients more time. Ottawa Hospital Research Institute. https://archive.ph/qwg6g
Buchanan, A. (2019, January 30). Flu vaccination keeps people with COPD out of the hospital. Ottawa Hospital Research Institute. https://archive.ph/nu0oI
Andrew McRae. (2019, November 26). Cumming School of Medicine. https://archive.ph/oi8C8
Andrew McRae. The Rotman Institute of Philosophy. Retrieved January 10, 2022, from https://archive.ph/9RMci
McRae, A. (2021). Declaration of competing interests. Canadian Medical Association Journal. https://archive.ph/AphOI
Slobodan, J. (2017, May 9). Provision of Docusate for Spinal Cord Injury (SCI) Patients. Alberta Health Services. https://archive.ph/pG2KD
Weltz, L. (2020, May). Always on alert for health threats. Alberta Doctors’ Digest. https://archive.ph/7akGj/
Poliquin, G., Forgie, S., Zelyas, N., & Charlton, C. (2021). Challenges in COVID-19 Laboratory Testing. Association of Medical Microbiology and Infectious Disease (AMMI) Canada (p. 3). Public Health Agency of Canada. https://ammi.ca/wp-content/uploads/2021/08/CUPA-TEA-Challenges-in-COVID-19-diagnostics-FINAL.pdf
Novel Coronavirus (2019-nCoV) Laboratory Update. (2020, January 31). Alberta Health Services; Alberta Precision Laboratories. https://archive.ph/wph4a
Contact | Laboratory Medicine and Pathology. University of Alberta. Retrieved January 10, 2022, from https://archive.ph/NKRka
Zelyas, N., Pabbaraju, K., Croxen, M. A., Lynch, T., Buss, E., Murphy, S. A., Shokoples, S., Wong, A., Kanji, J. N., & Tipples, G. (2021). Precision Response to the Rise of the SARS-CoV-2 B.1.1.7 Variant of Concern by Combining Novel PCR Assays and Genome Sequencing for Rapid Variant Detection and Surveillance. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00315-21
BIOTECanada. (2021, October 15). Canada’s Vaccine Industry Committee. Retrieved December 6, 2021, from http://www.biotech.ca/policy-matters/health/canadas-vaccine-industry-committee/
South China Vaccine Corporation. ABOUT US. Retrieved December 6, 2021, from http://www.gdscvc.com/about
Vaccine and Infectious Disease Organization (VIDO). Annual Report 2019–2020. Retrieved December 6, 2021, from https://www.vido.org/assets/upload/pdf/annual_reports/VIDO%20-%20Annual%20Report%202019-2020.pdf
Weber, B. (2020, December 1). Public health must balance science and society: former top doctor. CBC News; The Canadian Press. https://archive.ph/UcuAi
CTV Calgary. (2012, March 28). Alberta’s top doc resigns. CTV News. https://archive.ph/GFjmw
Williams, N. (2019, October 30). New Board of Directors at the Canadian Partnership Against Cancer. Canadian Partnership against Cancer. https://archive.ph/vkv2w
Annual Report 2020/2021. Canadian Partnership Against Cancer. Retrieved January 10, 2022, from https://s22457.pcdn.co/wp-content/uploads/2021/09/Annual-report-2020-2021-EN.pdf
COVID-19 Wastewater Coalition. Canadian Water Network. Retrieved January 10, 2022, from https://archive.ph/BezDZ
Healy, D. (2012, March 29). Appointment of New Chief Public Health Officer. Government of Northwest Territories. https://archive.ph/AXB2J
Well done! I think this is so important to follow the trail of money and connections. The suppression of early treatments has been criminal, and one of the most disturbing aspects of all of this.